Skip to main content
Top
Published in: Journal of Gastroenterology 10/2020

01-10-2020 | Rectal Cancer | Original Article–Alimentary Tract

Prognostic impact of primary tumor location in Stage III colorectal cancer-right-sided colon versus left-sided colon versus rectum: a nationwide multicenter retrospective study

Authors: Dai Shida, Manabu Inoue, Taro Tanabe, Konosuke Moritani, Shunsuke Tsukamoto, Shinichi Yamauchi, Kenichi Sugihara, Yukihide Kanemitsu

Published in: Journal of Gastroenterology | Issue 10/2020

Login to get access

Abstract

Background

Previous studies investigating the impact of tumor location on colorectal cancer prognosis only compared two groups by location, e.g., ‘right-sided colon vs. left-sided colon,’ ‘colon vs. rectum,’ and ‘right-sided (right-sided colon) vs. left-sided (left-sided colon and rectum).’ This nationwide multicenter retrospective study aimed to clarify the prognostic impact of tumor location in patients with stage III colorectal cancer by classifying tumors into three groups: right-sided colon, left-sided colon, and rectum.

Methods

Subjects were 9194 patients with stage III colorectal cancer who underwent curative surgery from 1997 to 2012. Relapse-free survival (RFS) after primary surgery and overall survival (OS) after recurrence were examined.

Results

Rectal cancer (n = 2922) was associated with worse RFS compared to right-sided colon cancer (n = 2362) (hazard ratio (HR) 0.65; 95% CI 0.59–0.72; p < 0.001) and left-sided colon cancer (n = 3910) (HR 0.72; 95% CI 0.66–0.78; p < 0.001) after adjusting for key clinical factors (i.e., sex, age, histological type, CEA, adjuvant therapy, T category, and N category). Among patients with recurrence (n = 2823), rectal cancer was associated with better OS compared to right-sided colon cancer (HR 1.23; 95% CI 1.08–1.40; p = 0.002) and worse OS compared to left-sided colon cancer (HR 0.88; 95% CI 0.79–0.99; p = 0.029). Twenty percent of right-sided colon cancer recurrences exhibited peritoneal dissemination, 42% of left-sided colon cancer recurrences were liver metastases, and 33% of rectal cancer recurrences were local recurrences.

Conclusions

The three tumor locations (right-sided colon, left-sided colon, rectum) had different prognostic implications for recurrence after curative resection and overall mortality, suggesting that tumor location serves as a prognostic biomarker in stage III colorectal cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713–29.CrossRef Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713–29.CrossRef
2.
go back to reference Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3:194–201.CrossRef Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3:194–201.CrossRef
3.
go back to reference Shida D, Tanabe T, Boku N, et al. Prognostic value of primary tumor sidedness for unresectable stage IV colorectal cancer: a retrospective study. Ann Surg Oncol. 2019;26:1358–65.CrossRef Shida D, Tanabe T, Boku N, et al. Prognostic value of primary tumor sidedness for unresectable stage IV colorectal cancer: a retrospective study. Ann Surg Oncol. 2019;26:1358–65.CrossRef
4.
go back to reference Shida D. ASO author reflections: prognostic impact of primary tumor sidedness for unresectable stage IV colorectal cancer. Ann Surg Oncol. 2019;26:666–7.CrossRef Shida D. ASO author reflections: prognostic impact of primary tumor sidedness for unresectable stage IV colorectal cancer. Ann Surg Oncol. 2019;26:666–7.CrossRef
5.
go back to reference Kamath SD, Khorana AA. Does sidedness matter in unresectable colorectal cancer? Ann Surg Oncol. 2019;26:1588–91.PubMed Kamath SD, Khorana AA. Does sidedness matter in unresectable colorectal cancer? Ann Surg Oncol. 2019;26:1588–91.PubMed
6.
go back to reference Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs. right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3:211–9.CrossRef Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs. right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3:211–9.CrossRef
7.
go back to reference Ha GW, Kim JH, Lee MR. Oncologic effects of primary tumor-sidedness on patients with stages 1–3 colon cancer: a meta-analysis. Ann Surg Oncol. 2019;26:1366–75.PubMed Ha GW, Kim JH, Lee MR. Oncologic effects of primary tumor-sidedness on patients with stages 1–3 colon cancer: a meta-analysis. Ann Surg Oncol. 2019;26:1366–75.PubMed
8.
go back to reference Yahagi M, Okabayashi K, Hasegawa H, et al. The worse prognosis of right-sided compared with left-sided colon cancers: a systematic review and meta-analysis. J Gastrointest Surg. 2016;20:648–55.PubMed Yahagi M, Okabayashi K, Hasegawa H, et al. The worse prognosis of right-sided compared with left-sided colon cancers: a systematic review and meta-analysis. J Gastrointest Surg. 2016;20:648–55.PubMed
9.
go back to reference Karim S, Brennan K, Nanji S, et al. Association between prognosis and tumor laterality in early-stage colon cancer. JAMA Oncol. 2017;3:1386–92.PubMedPubMedCentral Karim S, Brennan K, Nanji S, et al. Association between prognosis and tumor laterality in early-stage colon cancer. JAMA Oncol. 2017;3:1386–92.PubMedPubMedCentral
10.
go back to reference Warschkow R, Sulz MC, Marti L, et al. Better survival in right-sided versus left-sided stage I-III colon cancer patients. BMC Cancer. 2016;16:554.CrossRef Warschkow R, Sulz MC, Marti L, et al. Better survival in right-sided versus left-sided stage I-III colon cancer patients. BMC Cancer. 2016;16:554.CrossRef
11.
go back to reference Ishihara S, Murono K, Sasaki K, et al. Impact of primary tumor location on postoperative recurrence and subsequent prognosis in nonmetastatic colon cancers: a multicenter retrospective study using a propensity score analysis. Ann Surg. 2018;267:917–21.CrossRef Ishihara S, Murono K, Sasaki K, et al. Impact of primary tumor location on postoperative recurrence and subsequent prognosis in nonmetastatic colon cancers: a multicenter retrospective study using a propensity score analysis. Ann Surg. 2018;267:917–21.CrossRef
12.
go back to reference Kishiki T, Kuchta K, Matsuoka H, et al. The impact of tumor location on the biological and oncological differences of colon cancer: Multi-institutional propensity score-matched study. Am J Surg. 2019;217:46–52.CrossRef Kishiki T, Kuchta K, Matsuoka H, et al. The impact of tumor location on the biological and oncological differences of colon cancer: Multi-institutional propensity score-matched study. Am J Surg. 2019;217:46–52.CrossRef
13.
go back to reference Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75.CrossRef Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75.CrossRef
14.
go back to reference Benson AB 3rd, Venook AP, Cederquist L, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:370–98.CrossRef Benson AB 3rd, Venook AP, Cederquist L, et al. Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:370–98.CrossRef
15.
go back to reference Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:874–901.CrossRef Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:874–901.CrossRef
16.
go back to reference Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2019;25:1–42.CrossRef Hashiguchi Y, Muro K, Saito Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2019;25:1–42.CrossRef
17.
go back to reference UICC. TNM classification of malignant tumours eighth edition. Brierley JD, Gospodarowicz MK, Wittekind C, editors. New York: John Wiley and Sons, Ltd; 2017. UICC. TNM classification of malignant tumours eighth edition. Brierley JD, Gospodarowicz MK, Wittekind C, editors. New York: John Wiley and Sons, Ltd; 2017.
18.
go back to reference Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601–9.CrossRef Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601–9.CrossRef
19.
go back to reference Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.CrossRef Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.CrossRef
20.
go back to reference Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016;17:1709–19.PubMed Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016;17:1709–19.PubMed
21.
go back to reference Shida D, Yoshida T, Tanabe T, et al. Prognostic impact of R0 resection and targeted therapy for colorectal cancer with synchronous peritoneal metastasis. Ann Surg Oncol. 2018;25:1646–53.PubMed Shida D, Yoshida T, Tanabe T, et al. Prognostic impact of R0 resection and targeted therapy for colorectal cancer with synchronous peritoneal metastasis. Ann Surg Oncol. 2018;25:1646–53.PubMed
22.
go back to reference Akiyoshi T, Watanabe T, Miyata S, et al. Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease? Ann Surg. 2012;255:1129–34.PubMed Akiyoshi T, Watanabe T, Miyata S, et al. Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease? Ann Surg. 2012;255:1129–34.PubMed
23.
go back to reference Sinicrope FA, Mahoney MR, Yoon HH, et al. Analysis of molecular markers by anatomic tumor site in stage III colon carcinomas from adjuvant chemotherapy trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015;21:5294–304.PubMedPubMedCentral Sinicrope FA, Mahoney MR, Yoon HH, et al. Analysis of molecular markers by anatomic tumor site in stage III colon carcinomas from adjuvant chemotherapy trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015;21:5294–304.PubMedPubMedCentral
24.
go back to reference Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61:847–54.PubMedPubMedCentral Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61:847–54.PubMedPubMedCentral
25.
go back to reference Taieb J, Shi Q, Pederson L, et al. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol. 2019;30:1466–71.PubMedPubMedCentral Taieb J, Shi Q, Pederson L, et al. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. Ann Oncol. 2019;30:1466–71.PubMedPubMedCentral
26.
go back to reference Shida D, Ochiai H, Tsukamoto S, et al. Long-term outcomes of laparoscopic versus open D3 dissection for stage II/III colon cancer: Results of propensity score analyses. Eur J Surg Oncol. 2018;44:1025–30.PubMed Shida D, Ochiai H, Tsukamoto S, et al. Long-term outcomes of laparoscopic versus open D3 dissection for stage II/III colon cancer: Results of propensity score analyses. Eur J Surg Oncol. 2018;44:1025–30.PubMed
27.
go back to reference Pai RK, Jayachandran P, Koong AC, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol. 2012;36:744–52.PubMedPubMedCentral Pai RK, Jayachandran P, Koong AC, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol. 2012;36:744–52.PubMedPubMedCentral
28.
go back to reference Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623–32.PubMedPubMedCentral Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623–32.PubMedPubMedCentral
29.
go back to reference Aoyama T, Oba K, Honda M, et al. Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients’ data from three large phase III randomized trials. Cancer Med. 2017;6:1573–80.PubMedPubMedCentral Aoyama T, Oba K, Honda M, et al. Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients’ data from three large phase III randomized trials. Cancer Med. 2017;6:1573–80.PubMedPubMedCentral
30.
go back to reference Ho YH, Siu SK, Buttner P, et al. The effect of obstruction and perforation on colorectal cancer disease-free survival. World J Surg. 2010;34:1091–101.CrossRef Ho YH, Siu SK, Buttner P, et al. The effect of obstruction and perforation on colorectal cancer disease-free survival. World J Surg. 2010;34:1091–101.CrossRef
31.
go back to reference Carraro PG, Segala M, Orlotti C, et al. Outcome of large-bowel perforation in patients with colorectal cancer. Dis Colon Rectum. 1998;41:1421–6.CrossRef Carraro PG, Segala M, Orlotti C, et al. Outcome of large-bowel perforation in patients with colorectal cancer. Dis Colon Rectum. 1998;41:1421–6.CrossRef
Metadata
Title
Prognostic impact of primary tumor location in Stage III colorectal cancer-right-sided colon versus left-sided colon versus rectum: a nationwide multicenter retrospective study
Authors
Dai Shida
Manabu Inoue
Taro Tanabe
Konosuke Moritani
Shunsuke Tsukamoto
Shinichi Yamauchi
Kenichi Sugihara
Yukihide Kanemitsu
Publication date
01-10-2020
Publisher
Springer Singapore
Published in
Journal of Gastroenterology / Issue 10/2020
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-020-01706-7

Other articles of this Issue 10/2020

Journal of Gastroenterology 10/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.